Certified Diabetes Educators Host First Known 24-Hour Diabetes Online Chat-A-Thon

DiabetesWATCH.com Kick-off Focuses on Managing Diabetes 24 Hours a Day



Apr 12, 2001, 01:00 ET from Aventis Pharmaceuticals

    BRIDGEWATER, N.J., April 12 /PRNewswire/ -- People living with diabetes
 can learn more about controlling their disease by participating in a 24-hour
 online chat-a-thon with health care experts who specialize in diabetes care.
 The chat-a-thon will begin at 6 a.m. EST April 26 and last until 6 a.m. EST
 April 27 on DiabetesWATCH.com, a new Web site devoted to diabetes education.
     Diabetes must be managed 24 hours a day, seven days a week, and the
 chat-a-thon is designed to help people learn to control their disease.  During
 the chat-a-thon, individuals with diabetes and interested caregivers can
 interact in "real time" with certified diabetes educators (CDEs), health care
 professionals from the American Association of Diabetes Educators (AADE) who
 develop day-to-day health management strategies to aid people in achieving and
 maintaining control of diabetes.
     Participants can ask educators about a variety of topics, including how a
 chronic disease can impact their lives, why successful glucose control results
 in better overall health, why it is important to recognize symptoms, and what
 kind of physician to see.
     Questions and educators' respective answers can be viewed during the
 event's uninterrupted 24 hours, and transcripts of highlights will be posted
 on the site afterward.  While CDEs will moderate specific chats, the event
 also includes open sessions.
     "A live 24-hour chat-a-thon -- where people can discuss their issues and
 receive immediate answers -- is a wonderful way to reach people who have no
 access to our services," said Ginger Kanzer-Lewis, RNC, EdM, CDE, and
 president of the AADE.  "The American Association of Diabetes Educators is
 pleased to be a part of this exciting event, and our members are delighted to
 help provide current information and education through a new venue."
     The continuous 24-hour chat-a-thon is believed to be the first of its kind
 in scope and duration.
     The chat-a-thon officially launches DiabetesWATCH.com, a Web site that
 provides users with instant access to multiple tools which may assist in
 controlling their diabetes.  It offers a 24-hour support system in which
 people with diabetes can privately share tips and personal stories through
 chat rooms and discussion groups.  People also can browse recent health news
 from leading medical journals, schedule doctor visits, track medication, count
 carbohydrates, and receive disease and lifestyle advice from an online
 clinical diabetes educator while on the site.
     "The more self-management education we can give to people with this
 chronic disease, which has been branded an epidemic by the Centers for Disease
 Control, the better the public may be able to prevent its devastating
 complications and improve the quality of their lives," said Kanzer-Lewis.
     Aventis Pharmaceuticals and the American Association of Diabetes Educators
 are coordinating the chat-a-thon.  Aventis Pharmaceuticals created
 DiabetesWATCH.com to promote awareness and understanding of diabetes and to
 help those with the disease live healthier lives.
     Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG.
 With headquarters in Bridgewater, N.J., Aventis Pharmaceuticals focuses its
 activities on important therapeutic areas such as cardiology, oncology,
 anti-infectives, arthritis, allergy and respiratory, diabetes, and the central
 nervous system.
     Aventis Pharma AG is the pharmaceutical company of Aventis S.A.
 (NYSE:   AVE).  Aventis Pharma is dedicated to treating and preventing human
 disease through the discovery, development, manufacture, and sale of
 innovative pharmaceutical products aimed at fulfilling unmet medical needs.
 The corporate headquarters of Aventis Pharma is in Frankfurt, Germany.
 Aventis Pharma is comprised of Aventis Pasteur, a world leader in vaccines,
 headquartered in Lyon, France, and Aventis Behring, a world leader in
 therapeutic proteins, headquartered in King of Prussia, P.A.
     Aventis S.A., a world leader in pharmaceuticals and agriculture, is
 headquartered in Strasbourg, France.  The company employs approximately
 95,000 people in more than 120 countries.  Aventis was launched in December
 1999 through the merger of Hoechst AG and Rhone-Poulenc S.A.
 
     The AADE is a non-profit organization that focuses on education and
 communication to diabetes audiences.  It represents more than 10,000 health
 professionals who are dedicated to advancing the role of the diabetes educator
 and improving the quality of diabetes education and care.  Upon completion of
 AADE requirements, nurses, dieticians, pharmacists, exercise specialists,
 doctors, and social workers who specialize in diabetes care become CDEs.  CDEs
 work in a variety of settings to teach patients how to better manage diabetes,
 including how to achieve and maintain 24-hour control of the disease.
     To receive a copy of this release or any recent release via fax, call
 Aventis Pharmaceuticals' automated news fax line at 800/556-7422.  You also
 may visit the Aventis Pharmaceuticals U.S. Web site at
 http://www.aventispharma-us.com .
 
     DiabetesWATCH is a diabetes information and management application
 published over the Internet and is intended only to assist patients to monitor
 their personal health information and to provide broad consumer understanding
 and knowledge of diabetes health topics.  The information should not be used
 in place of visit, call, consultation or advice of your physician or other
 health care provider.
     This service does not recommend the self-management of health problems.
 Information obtained by using this service is not exhaustive and does not
 cover all ailments, physical conditions or their treatment.
     Should you have any health care-related questions, please call or see your
 physician or other health care provider promptly.  You should never disregard
 medical advice or delay in seeking it because of something you have read here.
 USERS ARE URGED AND ADVISED TO SEEK THE ADVICE OF A PHYSICIAN BEFORE BEGINNING
 ANY TREATMENT.
     Statements in this news release other than historical information are
 forward-looking statements subject to risks and uncertainties.  Actual results
 could differ materially depending on factors such as the availability of
 resources, the timing and effects of regulatory actions, the strength of
 competition, the outcome of litigation, and the effectiveness of patent
 protection.  Additional information regarding risks and uncertainties is set
 forth in the current Annual Report on Form 20-F of Aventis on file with the
 Securities and Exchange Commission.
 
     CONTACT:  Lisa Kennedy of Aventis Pharmaceuticals, 908-243-6361.
 
     1172C1
 
 

SOURCE Aventis Pharmaceuticals
    BRIDGEWATER, N.J., April 12 /PRNewswire/ -- People living with diabetes
 can learn more about controlling their disease by participating in a 24-hour
 online chat-a-thon with health care experts who specialize in diabetes care.
 The chat-a-thon will begin at 6 a.m. EST April 26 and last until 6 a.m. EST
 April 27 on DiabetesWATCH.com, a new Web site devoted to diabetes education.
     Diabetes must be managed 24 hours a day, seven days a week, and the
 chat-a-thon is designed to help people learn to control their disease.  During
 the chat-a-thon, individuals with diabetes and interested caregivers can
 interact in "real time" with certified diabetes educators (CDEs), health care
 professionals from the American Association of Diabetes Educators (AADE) who
 develop day-to-day health management strategies to aid people in achieving and
 maintaining control of diabetes.
     Participants can ask educators about a variety of topics, including how a
 chronic disease can impact their lives, why successful glucose control results
 in better overall health, why it is important to recognize symptoms, and what
 kind of physician to see.
     Questions and educators' respective answers can be viewed during the
 event's uninterrupted 24 hours, and transcripts of highlights will be posted
 on the site afterward.  While CDEs will moderate specific chats, the event
 also includes open sessions.
     "A live 24-hour chat-a-thon -- where people can discuss their issues and
 receive immediate answers -- is a wonderful way to reach people who have no
 access to our services," said Ginger Kanzer-Lewis, RNC, EdM, CDE, and
 president of the AADE.  "The American Association of Diabetes Educators is
 pleased to be a part of this exciting event, and our members are delighted to
 help provide current information and education through a new venue."
     The continuous 24-hour chat-a-thon is believed to be the first of its kind
 in scope and duration.
     The chat-a-thon officially launches DiabetesWATCH.com, a Web site that
 provides users with instant access to multiple tools which may assist in
 controlling their diabetes.  It offers a 24-hour support system in which
 people with diabetes can privately share tips and personal stories through
 chat rooms and discussion groups.  People also can browse recent health news
 from leading medical journals, schedule doctor visits, track medication, count
 carbohydrates, and receive disease and lifestyle advice from an online
 clinical diabetes educator while on the site.
     "The more self-management education we can give to people with this
 chronic disease, which has been branded an epidemic by the Centers for Disease
 Control, the better the public may be able to prevent its devastating
 complications and improve the quality of their lives," said Kanzer-Lewis.
     Aventis Pharmaceuticals and the American Association of Diabetes Educators
 are coordinating the chat-a-thon.  Aventis Pharmaceuticals created
 DiabetesWATCH.com to promote awareness and understanding of diabetes and to
 help those with the disease live healthier lives.
     Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG.
 With headquarters in Bridgewater, N.J., Aventis Pharmaceuticals focuses its
 activities on important therapeutic areas such as cardiology, oncology,
 anti-infectives, arthritis, allergy and respiratory, diabetes, and the central
 nervous system.
     Aventis Pharma AG is the pharmaceutical company of Aventis S.A.
 (NYSE:   AVE).  Aventis Pharma is dedicated to treating and preventing human
 disease through the discovery, development, manufacture, and sale of
 innovative pharmaceutical products aimed at fulfilling unmet medical needs.
 The corporate headquarters of Aventis Pharma is in Frankfurt, Germany.
 Aventis Pharma is comprised of Aventis Pasteur, a world leader in vaccines,
 headquartered in Lyon, France, and Aventis Behring, a world leader in
 therapeutic proteins, headquartered in King of Prussia, P.A.
     Aventis S.A., a world leader in pharmaceuticals and agriculture, is
 headquartered in Strasbourg, France.  The company employs approximately
 95,000 people in more than 120 countries.  Aventis was launched in December
 1999 through the merger of Hoechst AG and Rhone-Poulenc S.A.
 
     The AADE is a non-profit organization that focuses on education and
 communication to diabetes audiences.  It represents more than 10,000 health
 professionals who are dedicated to advancing the role of the diabetes educator
 and improving the quality of diabetes education and care.  Upon completion of
 AADE requirements, nurses, dieticians, pharmacists, exercise specialists,
 doctors, and social workers who specialize in diabetes care become CDEs.  CDEs
 work in a variety of settings to teach patients how to better manage diabetes,
 including how to achieve and maintain 24-hour control of the disease.
     To receive a copy of this release or any recent release via fax, call
 Aventis Pharmaceuticals' automated news fax line at 800/556-7422.  You also
 may visit the Aventis Pharmaceuticals U.S. Web site at
 http://www.aventispharma-us.com .
 
     DiabetesWATCH is a diabetes information and management application
 published over the Internet and is intended only to assist patients to monitor
 their personal health information and to provide broad consumer understanding
 and knowledge of diabetes health topics.  The information should not be used
 in place of visit, call, consultation or advice of your physician or other
 health care provider.
     This service does not recommend the self-management of health problems.
 Information obtained by using this service is not exhaustive and does not
 cover all ailments, physical conditions or their treatment.
     Should you have any health care-related questions, please call or see your
 physician or other health care provider promptly.  You should never disregard
 medical advice or delay in seeking it because of something you have read here.
 USERS ARE URGED AND ADVISED TO SEEK THE ADVICE OF A PHYSICIAN BEFORE BEGINNING
 ANY TREATMENT.
     Statements in this news release other than historical information are
 forward-looking statements subject to risks and uncertainties.  Actual results
 could differ materially depending on factors such as the availability of
 resources, the timing and effects of regulatory actions, the strength of
 competition, the outcome of litigation, and the effectiveness of patent
 protection.  Additional information regarding risks and uncertainties is set
 forth in the current Annual Report on Form 20-F of Aventis on file with the
 Securities and Exchange Commission.
 
     CONTACT:  Lisa Kennedy of Aventis Pharmaceuticals, 908-243-6361.
 
     1172C1
 
 SOURCE  Aventis Pharmaceuticals